Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin

American Journal of Roentgenology

Volumn 195, Issue 6, 2010, Pages 1404-1410

  Oh, Jong Ryool ^a   Song, Ho Chun ^a   Chong, Ari ^a   Ha, Jung Min ^a   Jeong, Shin Young ^a   Min, Jung Joon ^a   Bom, Hee Seung ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Diabetes mellitus; FDG; Intestines; Metformin; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOSE; METFORMIN;

ADULT; ARTICLE; COLORECTAL DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINES; MALE; METFORMIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78649723342     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4663     Document Type: Article

References (31)

1. Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37:441-446
2. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005; 33:145-155
3. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake: the role of PET/ CT. Eur Radiol 2006; 16:1054-1065
4. 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34:122-133
5. Kim S, Chung JK, Kim BT, et al. Relationship between gastrointestinal F-18-fluorodeoxyglucose accumulation and gastrointestinal symptoms in wholebody PET. Clin Positron Imaging 1999; 2:273-279
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy - a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963-1972
7. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5:157-167
8. Bosi E. Metformin: the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 2009; 11:3-8
9. 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 2008; 35:95-99
10. 18F-FDG PET/CT uptake. Presse Med 2009; 38:686-687
11. 18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging 2010; 37:1011-1017
12. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30:359-371
13. Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab 2007; 9:483-489 (Pubitemid 47018511)
14. Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/ CT. AJR 2005; 185:495-500
15. 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005; 46:758-762
16. 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45:1804-1810
17. Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA. Bowel hot spots at PET-CT. RadioGraphics 2007; 27:145-159
18. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002; 224:783-787
19. Caspary WF, Creutzfeldt W. Analysis of the inhibitory effect of biguanides on glucose absorption: inhibition of active sugar transport. Diabetologia 1971; 7:379-385
20. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 2000; 59:887-890
21. Lorch E. Inhibition of intestinal absorption and improvement of oral glucose tolerance by biguanides in the normal and in the streptozotocin-diabetic rat. Diabetologia 1971; 7:195-203
22. Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol 1991; 43:120-121
23. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63:1879-1894
24. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579
25. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008; 51:1552-1553
26. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994; 112:671-675
27. Lenzen S, Lortz S, Tiedge M. Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats. Biochem Pharmacol 1996; 51:893-896
28. Penicaud L, Hitier Y, Ferre P, Girard J. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989; 262: 881-885
29. Drozdowski LA, Thomson AB. Intestinal sugar transport. World J Gastroenterol 2006; 12:1657-1670
30. Wright EM, Martin MG, Turk E. Intestinal absorption in health and disease - sugars. Best Pract Res Clin Gastroenterol 2003; 17:943-956
31. Walker J, Jijon HB, Diaz H, Salehi P, Churchill T, Madsen KL. 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. Biochem J 2005; 385:485-491